| __timestamp | MiMedx Group, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 5078000000 |
| Thursday, January 1, 2015 | 133384000 | 4717000000 |
| Friday, January 1, 2016 | 179997000 | 5096000000 |
| Sunday, January 1, 2017 | 220119000 | 4986000000 |
| Monday, January 1, 2018 | 258528000 | 4214000000 |
| Tuesday, January 1, 2019 | 198205000 | 3806000000 |
| Wednesday, January 1, 2020 | 181022000 | 3671000000 |
| Friday, January 1, 2021 | 198359000 | 3528000000 |
| Saturday, January 1, 2022 | 208789000 | 3445000000 |
| Sunday, January 1, 2023 | 211124000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and MiMedx Group, Inc. from 2014 to 2023. Over this period, Teva consistently reported higher SG&A costs, peaking in 2016 with expenses nearly 50 times greater than MiMedx. However, Teva's expenses have shown a downward trend, decreasing by approximately 32% from 2016 to 2023. In contrast, MiMedx's SG&A expenses have grown steadily, increasing by about 133% over the same period. This divergence highlights differing strategic priorities and operational scales. Teva's reduction may indicate cost-cutting measures or efficiency improvements, while MiMedx's rise could reflect expansion efforts. These insights offer a window into the financial strategies shaping the pharmaceutical landscape.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Teva Pharmaceutical Industries Limited vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Rhythm Pharmaceuticals, Inc. and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Celldex Therapeutics, Inc. and MiMedx Group, Inc.